BOUSBIB ARI sold $26.1M of IQV

BOUSBIB ARI (See Remarks) sold 106,279 shares of IQVIA HOLDINGS INC. (IQV) at an average of $245.51 ($244.78–$247.10, $26.09M total) across 4 trades on 2026-07-29.

Original reporting
SEC EDGAR · BOUSBIB ARI
Published Jul 31, 2026, 9:02 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 31, 2026, 9:06 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$IQV
Neutral
low confidence
Mentioned
$IQV
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$IQVNeutralLow
01

Why it matters

The newest fact is the disclosed sale size ($26.09M) and the trade price range ($244.78 to $247.10) by an officer/director on 2026-07-29.

02

Market read

Traders may monitor for follow-on insider activity or interpret the sale as mild negative sentiment, but there is no new operating or financial guidance in the filing.

03

What to watch

The text does not state whether the sale was part of a broader program, tax event, or diversification plan, and it provides no context on prior insider activity.

Relevance 7/10Novelty 5/10Timing: filed 2026-07-31 after trades dated 2026-07-29

Background

This is an SEC Form 4 insider transaction disclosure for IQVIA Holdings Inc.

Company-level read

Ticker impact

$IQVNeutralLow confidence
Context

IQVIA Form 4 shows officer/director BOUSBIB ARI sold $26.1M of IQV shares in open-market transactions at $244.78 to $247.10 on 2026-07-29.

Expected impact

Likely limited, short-lived sentiment impact unless follow-on selling or new fundamentals emerge.

Evidence & confidence

The filing is a routine Form 4 insider sale with no 10b5-1 plan stated and no accompanying company-specific operational update in the text.

Market effects

No sector-wide read-through is provided; this is company-specific insider activity only.

None indicated.

None indicated.

Counterpoint

Insider sales can be planned for liquidity or diversification, so the signal may be overstated without evidence of distress or a 10b5-1 plan.

Key entities

  • IQVIA HOLDINGS INC.

    Subject of the Form 4 insider sale disclosure.

  • BOUSBIB ARI

    Officer and director who sold 106,279 shares across four trades.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$IQVHighAI 8/10

5 revealing analyst questions from IQVIA’s Q3 earnings call

IQVIA reported Q3 revenue of $4.43 billion, beating estimates by 1.5%, with adjusted EPS of $3.34, a 2% beat. The company raised full-year revenue guidance to $17.43 billion. Analysts discussed AI-driven workflows, margin improvements, and clinical bookings during the earnings call. CEO Ari Bousbib highlighted proprietary data and life sciences expertise as key differentiators.

$IQVMedAI 8/10

IQVIA Holdings Inc (IQV) (Q3 2026) Earnings Call Highlights: Record Bookings, Raised

IQVIA Holdings Inc. reported Q3 2026 earnings with record bookings and raised guidance. Revenue was $4.428B, up 8% YoY, and adjusted EBITDA rose 8.7%. Challenges include FX headwinds and R&D backlog adjustments. Management highlighted AI adoption and strong biotech demand. Full-year 2026 guidance was increased, with revenue expected between $17.35B-$17.5B. No 2027 guidance was provided.

$IQVHighAI 8/10

What IQVIA (IQV) Said on Its Q3 Earnings Call

IQVIA reported Q3 revenue growth of 6.9% to $1.79B, with organic growth at 4%. AI adoption contributed to commercial and clinical momentum, with 415 AI agents deployed. The company raised its 2026 outlook, expecting revenue of $17.35B-$17.50B and adjusted EPS of $12.90-$13.00. Cash flow from operations was $825M, with free cash flow at $667M.

$IQVHighAI 9/10

IQVIA (IQV) Q3 2026 Earnings Call Transcript

IQVIA reported Q3 2026 revenue of $4.43B, up 8%, with organic growth at 6%. Adjusted EBITDA grew 8.7% to $1.03B, and adjusted EPS rose 11.3% to $3.34. R&D solutions revenue increased 8.7%, and commercial solutions revenue grew 6.9%. The company raised full-year revenue guidance to $17.35B-$17.5B. AI deployments and emerging biopharma funding growth were highlighted.